Overview

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
Phase:
PHASE1
Details
Lead Sponsor:
Guangzhou JOYO Pharma Co., Ltd